Alefacept
- Generic Name
- Alefacept
- Drug Type
- Biotech
- CAS Number
- 222535-22-0
- Unique Ingredient Identifier
- ELK3V90G6C
- Background
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
- Indication
As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
- Conditions
- Moderate to Severe Psoriasis
- Interventions
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 18
- Registration Number
- NCT00678470
- Locations
- 🇺🇸
UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 78
- Registration Number
- NCT00674063
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 195
- Registration Number
- NCT00673556
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 185
- Registration Number
- NCT00659412
Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects
- Conditions
- Plaque Psoriasis
- Interventions
- Procedure: Narrow Band UVB Phototherapy
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 98
- Registration Number
- NCT00658606
Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 15
- Registration Number
- NCT00655564
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 75
- Registration Number
- NCT00653822
A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients
- Conditions
- De Novo Kidney Transplantation
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 218
- Registration Number
- NCT00617604
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 323
- Registration Number
- NCT00543569
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Methodist University Hospital - Memphis, Memphis, Tennessee, United States
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Drug: polyvalent pneumococcal vaccine
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 43
- Registration Number
- NCT00493324
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.